Halozyme Therapeutics | HALO - Sales Revenues


Halozyme Therapeutics reported $481M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 10.1B 1.48B Jun/2026
Baxter International USD 2.98B 20M Sep/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cytokinetics USD 28.6M 9.25M Jun/2026
DBV Technologies USD 645K 2.13M Dec/2025
Eli Lilly USD 24.4B 1.43B Sep/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 268M 22M Jun/2026
MannKind USD 109.37M 19.17M Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Pfizer USD 15.03B 530M Jun/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
United Therapeutics USD 783.3M 1.8M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024